Results 91 to 100 of about 1,095,233 (294)

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Inequality and inequity in eye health

Community Eye Health Journal, 2016
According to the 2010 Global Burden of Disease (GBD) study, the global prevalence of blindness (age-standardised) has declined from 0.60% in 1990 to 0.47% in 2010.
Johannes Trimmel
doaj  

Levodopa/carbidopa microtablets in Parkinson’s disease: a study of pharmacokinetics and blinded motor assessment [PDF]

, 2017
Marina Senek, Sten‐Magnus Aquilonius, Håkan Askmark, Filip Bergquist, Radu Constantinescu, Anders Ericsson, Sara Lycke, Alexander Medvedev, Mevludin Memedi, Fredrik Ohlsson, Jack Spira, Jerker Westin, Dag Nyholm   +12 more
openalex   +1 more source

Effect of Nonsteroidal Anti‐Inflammatory Drugs on Sacroiliac Joint Inflammation, as Seen on Magnetic Resonance Imaging, in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Objective Imaging evidence of active sacroiliitis is important for diagnosis, classification, and monitoring of axial spondyloarthritis (axSpA). However, there is no consistent guidance on whether patients should temporarily stop nonsteroidal anti‐inflammatory drugs (NSAIDs) before magnetic resonance imaging (MRI).
Gareth T. Jones, Alexander N. Bennett, Raj Sengupta, Pedro M. Machado, Helena Marzo‐Ortega, Lorna Aucott, Margaret A. Hall‐Craggs, Timothy J. P. Bray, Alan Bainbridge, Ruaridh M. Gollifer, Gary J. Macfarlane   +10 more
wiley   +1 more source

Hydroxychloroquine Associated with Lower Glomerular Filtration Rate Decline in Lupus Nephritis

Arthritis Care &Research, Accepted Article.
Background Hydroxychloroquine (HCQ) protects kidney function in lupus nephritis (LN) by preventing flares, yet some cohort studies show no significant benefit in kidney function with HCQ. Clarifying these conflicting findings by showing early and long‐term benefits of HCQ on kidney function preservation is critical. Therefore, we analyzed data from our
Shivani Garg, Brad Rovin, Brad C. Astor, Tripti Singh, Fauzia Hollnagel, Megan Kuik, Lexie Kolton, Callie Saric, S. Sam Lim, Christie M. Bartels   +9 more
wiley   +1 more source

Tackling inequality and inequity in eye health: can the SDGs help us?

Community Eye Health Journal, 2016
The Sustainable Development Goals (SDGs) were adopted at the United Nations (UN) General Assembly in September 2015. They are a set of goals and targets that all UN member states have committed to achieving: ‘to end poverty, protect the planet, and ...
Zoe Gray
doaj  

Improvements in Health‐Related Quality of Life with Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post‐hoc Analysis of a Randomized Multicenter Trial

Arthritis Care &Research, Accepted Article.
Background While treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL change.
Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls   +16 more
wiley   +1 more source

Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial [PDF]

, 2020
Philip J. Mease, M. Elaine Husni, Shelly Kafka, Soumya D. Chakravarty, Diane D. Harrison, Kim Hung Lo, Stephen Xu, Elizabeth C. Hsia, Arthur Kavanaugh   +8 more
openalex   +1 more source

Cost‐effectiveness of low dose colchicine prophylaxis when starting allopurinol using the “start‐low go‐slow” approach for gout: evidence from a non‐inferiority randomised double‐blind placebo‐controlled trial.

Arthritis Care &Research, Accepted Article.
Objective The aim of this study was to investigate the cost‐effectiveness of low‐dose colchicine prophylaxis for preventing gout flares when starting allopurinol using the “start‐low go‐slow” approach. Methods Participants with gout, fulfilling the American College of Rheumatology recommendations for starting urate‐lowering therapy and with serum urate
Yana Pryymachenko, Ross Wilson, Nicola Dalbeth, J. Haxby Abbott, Lisa Stamp   +4 more
wiley   +1 more source

Considerations for Issues of Regression to the Mean and Contextual Effects in Clinical Trials for Pain in Rheumatic Diseases

Arthritis Care &Research, EarlyView.
Recently, there has been growing discussion about how to best assess pain in clinical trials in rheumatic diseases. Reliable measurement of pain outcomes is essential for accurately determining the effectiveness of treatments. Although pain intensity is the most common measure of change in pain trials, other pain‐related measures, such as pain ...
Yen T. Chen, Guohao Zhu, Afton L. Hassett, Daniel Clauw, Susan L. Murphy   +4 more
wiley   +1 more source